Novo Nordisk and Hims & Hers have ended a legal feud with an agreement that allows the telehealth platform to sell the pharma giant’s blockbuster brand-name GLP-1 drugs. In separate statements issued ...

Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...

Health-care companies rose as a distribution spat was resolved. Wegovy maker Novo Nordisk said it was teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company's ...

COPENHAGEN, March 9 (Reuters) - Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers Health platform, ending a legal ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors ...

Novo Nordisk is dropping its lawsuit against Hims & Hers Health, as it has reached an agreement with the telehealth company. The deal will permit Hims & Hers Health to sell Ozempic and Wegovy on its ...